Dumontet C - Search Results

1

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.

Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Ghayad SE, et al. Among authors: dumontet c. Int J Cancer. 2010 Jan 15;126(2):545-62. doi: 10.1002/ijc.24750. Int J Cancer. 2010. PMID: 19609946

2

[Factors predictive of chemotherapy resistance in patients with breast cancer].

Dumontet C. Dumontet C. Ann Pathol. 2000;20 Suppl:S94. Ann Pathol. 2000. PMID: 11261312 French. No abstract available.

3

Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity.

Galmarini CM, Falette N, Tabone E, Levrat C, Britten R, Voorzanger-Rousselot N, Roesch-Gateau O, Vanier-Viornery A, Puisieux A, Dumontet C. Galmarini CM, et al. Among authors: dumontet c. Br J Cancer. 2001 Sep 14;85(6):902-8. doi: 10.1054/bjoc.2001.2017. Br J Cancer. 2001. PMID: 11556844 Free PMC article.

4

Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.

Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Galmarini CM, et al. Among authors: dumontet c. Int J Cancer. 2002 Feb 1;97(4):439-45. doi: 10.1002/ijc.1628. Int J Cancer. 2002. PMID: 11802204

5

Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics.

Galmarini CM, Kamath K, Vanier-Viornery A, Hervieu V, Peiller E, Falette N, Puisieux A, Ann Jordan M, Dumontet C. Galmarini CM, et al. Among authors: dumontet c. Br J Cancer. 2003 Jun 2;88(11):1793-9. doi: 10.1038/sj.bjc.6600960. Br J Cancer. 2003. PMID: 12771997 Free PMC article.

6

Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.

Galmarini CM, Clarke ML, Santos CL, Jordheim L, Perigaud C, Gosselin G, Cros E, Mackey JR, Dumontet C. Galmarini CM, et al. Among authors: dumontet c. Int J Cancer. 2003 Oct 20;107(1):149-54. doi: 10.1002/ijc.11339. Int J Cancer. 2003. PMID: 12925971

7

Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug.

Jordheim LP, Cros E, Gouy MH, Galmarini CM, Peyrottes S, Mackey J, Perigaud C, Dumontet C. Jordheim LP, et al. Among authors: dumontet c. Clin Cancer Res. 2004 Aug 15;10(16):5614-21. doi: 10.1158/1078-0432.CCR-04-0506. Clin Cancer Res. 2004. PMID: 15328204

8

cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.

Sève P, Mackey JR, Isaac S, Trédan O, Souquet PJ, Pérol M, Cass C, Dumontet C. Sève P, et al. Among authors: dumontet c. Lung Cancer. 2005 Sep;49(3):363-70. doi: 10.1016/j.lungcan.2005.04.008. Lung Cancer. 2005. PMID: 15923058

9

Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.

Jordheim LP, Guittet O, Lepoivre M, Galmarini CM, Dumontet C. Jordheim LP, et al. Among authors: dumontet c. Mol Cancer Ther. 2005 Aug;4(8):1268-76. doi: 10.1158/1535-7163.MCT-05-0121. Mol Cancer Ther. 2005. PMID: 16093443

10

A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells.

Galmarini CM, Bouchet BP, Audoynaud C, Lamblot C, Falette N, Bertholon J, Wang Q, Beghin A, Dumontet C, Puisieux A. Galmarini CM, et al. Among authors: dumontet c. Int J Cancer. 2006 Jul 1;119(1):60-6. doi: 10.1002/ijc.21770. Int J Cancer. 2006. PMID: 16432835

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

403 results

Search Page

Filters